Port Delivery System with Ranibizumab in patients with Diabetic Retinopathy with or without Diabetic Macular Edema

Brief description of study

The purpose of this study is to compare the effects, good or bad, of ranibizumab when it is delivered by an ocular (eye) implant (also known as the Port Delivery System with ranibizumab, or PDS) versus ranibizumab delivered by injections into the eye as treatment for Diabetic Macular Edema (DME). The ocular implant releases ranibizumab continuously (without stopping) over a long period of time into the back of the eye, and the contents of the implant can be exchanged with fresh ranibizumab by the study doctor. Because the implant continuously releases ranibizumab over time, patients may not need additional eye injections to treat their DME. This study will help determine whether ranibizumab delivered continuously through an ocular implant is similar in effectiveness to ranibizumab injections into the eye for treating patients with DME.

Clinical Study Identifier: s19-00729
ClinicalTrials.gov Identifier: NCT04108156
Principal Investigator: Yasha S Modi.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.